Evaluating the Efficacy of Bimekizumab Across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-Week Italian Multicenter Real-Life Lazio Experience.
Dermatology practical & conceptual(2025)
Key words
Bimekizumab, IL-17 Inhibition, Psoriatic Arthritis, IL-17, sensitives area, difficult to treat areas, psoriasis
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined